Specify a stock or a cryptocurrency in the search bar to get a summary
Anixa Biosciences Inc
ANIXAnixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer " primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Address: 3150 Almaden Expressway, San Jose, CA, United States, 95118
Analytics
WallStreet Target Price
8.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ANIX
Dividend Analytics ANIX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ANIX
Stock Valuation ANIX
Financials ANIX
Results | 2019 | Dynamics |